Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 2/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.30 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.30 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28454130 | 0.83 | NOS1 (0.34) | KMT2ALMNADGAT1NOS1NOS3 | |
| SCHEMBL25204323 | 0.80 | DGAT1 (0.37) | KMT2AMEN1GAALMNADGAT1 | |
| SCHEMBL4918011 | 0.78 | KMT2A (0.34) | KMT2AMEN1GAALMNADGAT1 | |
| SCHEMBL30231850 | 0.78 | — | — | |
| SCHEMBL7715983 | 0.75 | KMT2A (0.40) | KMT2AALDH1A1 | |
| SCHEMBL5209072 | 0.73 | ALDH1A1 (0.39) | KMT2AMEN1GAAALDH1A1MAPT | |
| SCHEMBL17093890 | 0.73 | NOS1 (0.36) | KMT2ALMNADGAT1NOS1NOS3 | |
| SCHEMBL221769 | 0.73 | ALDH1A1 (0.39) | KMT2AMEN1GAAALDH1A1MAPT | |
| SCHEMBL17093771 | 0.73 | NOS1 (0.36) | KMT2ALMNADGAT1NOS1NOS3 | |
| SCHEMBL7277029 | 0.73 | NOS1 (0.36) | KMT2ALMNADGAT1NOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024255806-A1 | PREPARATION AND USE OF HYDROGEL | 粤港澳大湾区精准医学研究院(广州) | 2024-12-19 | — | — | WO | claimed |
| CN-119144151-A | Preparation of hydrogels and uses thereof | 粤港澳大湾区精准医学研究院(广州) | 2024-12-17 | — | — | CN | claimed |
| CN-112375015-B | Preparation method of di-tert-butyloxycarbonyl aminooxy acetic acid | 安徽昊帆生物有限公司 | 2023-09-19 | — | — | CN | claimed |
| CN-113264967-B | Programmed death ligand-1 targeted compound and preparation method and application thereof | 江苏省原子医学研究所 | 2023-04-18 | — | — | CN | claimed |
| CN-112375015-A | Preparation method of di-tert-butyloxycarbonylaminoacetic acid | 安徽昊帆生物有限公司 | 2021-02-19 | — | — | CN | claimed |
| EP-4722227-A1 | COMPLEX, PHARMACEUTICAL COMPOSITION, VACCINE, AND APPLICATIONS THEREOF | ENU Pharma, Inc. (JP) | 2026-04-08 | — | — | EP | disclosed |
| US-12594350-B2 | CD8-specific capture agents, compositions, and methods of using and making | REGENERON PHARMACEUTICALS, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20250304623-A1 | PEPTIDES FOR INTRACELLULAR DELIVERY | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2025-10-02 | — | — | US | disclosed |
| US-12415831-B2 | HPLC free purification of peptides by the use of new capping and capture reagents | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| EP-4543900-A1 | PEPTIDES FOR INTRACELLULAR DELIVERY | Universidade de Santiago de Compostela (ES) | 2025-04-30 | — | — | EP | disclosed |
| EP-4541796-A1 | EXATECAN DERIVATIVES AND USE THEREOF | Hangzhou Adcoris Biopharma Co., Ltd (CN) | 2025-04-23 | — | — | EP | disclosed |
| WO-2025080711-A1 | DUAL PAYLOAD ANTIBODY DRUG CONJUGATES | SUTRO BIOPHARMA, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| EP-0831922-A2 | IMPROVED PHARMACEUTICAL COMPOSITIONS FOR GENE THERAPY | Therexsys Limited (GB) | 1998-04-01 | — | — | EP | disclosed |
| WO-1997014711-A9 | VITAMIN B12 RECEPTOR MODULATING AGENTS AND METHODS RELATED THERETO | — | 1997-10-02 | — | — | WO | disclosed |
| WO-1997014711-A1 | VITAMIN B12 RECEPTOR MODULATING AGENTS AND METHODS RELATED THERETO | RECEPTAGEN CORPORATION (US) | 1997-04-24 | — | — | WO | disclosed |
| EP-0754189-A1 | RECEPTOR MODULATING AGENTS AND METHODS RELATING THERETO | RECEPTAGEN CORPORATION (US) | 1997-01-22 | — | — | EP | disclosed |
| WO-1996041606-A2 | IMPROVED PHARMACEUTICAL COMPOSITIONS FOR GENE THERAPY | THEREXSYS LIMITED (GB) | 1996-12-27 | — | — | WO | disclosed |
| EP-0697891-A1 | POLYOXIME COMPOUNDS AND THEIR PREPARATION | Rose, Keith (CH) | 1996-02-28 | — | — | EP | disclosed |
| WO-1995027723-A1 | RECEPTOR MODULATING AGENTS AND METHODS RELATING THERETO | RECEPTAGEN CORPORATION (US) | 1995-10-19 | — | — | WO | disclosed |
| WO-1994025071-A1 | POLYOXIME COMPOUNDS AND THEIR PREPARATION | ROSE KEITH (CH) | 1994-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304623-A1 | PEPTIDES FOR INTRACELLULAR DELIVERY | LNPEP, TAP2, TMEM205 | KMT2A 3955/4885MEN1 1606/4885GAA 1250/4885 |
| US-12415831-B2 | HPLC free purification of peptides by the use of new capping and capture reagents | RNGTT, PTMS, RNMT | KMT2A 1747/4885MEN1 4819/4885GAA 591/4885 |
| US-12594350-B2 | CD8-specific capture agents, compositions, and methods of using and making | CD74, CD4, MICA | KMT2A 1486/4885MEN1 4582/4885GAA 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.